ERBB2 and breast cancer: We next tested whether germline mutations in CHEK2 alter PR positivity, because ER+/HER2− tumors can be either PR+ (strongly driven by ER signaling) or PR− constituting distinct breast cancer subtypes that coincide with Luminal A and B subtypes, respectively (see Table 1) (12).